What is the Sai Life Sciences PE ratio today?
Sai Life Sciences' PE ratio is 87.8 at the 29 October 2026 close (₹1,495.70 a share): a market capitalisation of ₹31,752 crore divided by consolidated net profit of ₹362 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹349 crore) it is 91.0.
Is Sai Life Sciences debt free?
No. Sai Life Sciences had borrowings of ₹95.1 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.04. Its cash and current investments were ₹158 crore, so it held net cash of ₹62.7 crore.
What is the Sai Life Sciences debt to equity ratio?
Sai Life Sciences' debt-to-equity ratio was 0.04 on 31 March 2026: borrowings of ₹95.1 crore against total equity of ₹2,484 crore. A year earlier, on 31 March 2025, it was 0.06.
What is the Sai Life Sciences PB ratio (price to book value)?
Sai Life Sciences' price-to-book (PB) ratio is 12.78 at the 29 October 2026 close: a market capitalisation of ₹31,752 crore divided by shareholders' equity (book value) of ₹2,484 crore on 31 March 2026. That is a book value of ₹117.00 per share against a share price of ₹1,495.70.
What is the Sai Life Sciences net worth?
Sai Life Sciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹2,484 crore on 31 March 2026, up 16.7% from ₹2,128 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹31,752 crore at the 29 October 2026 close.
What is the Sai Life Sciences ROE and ROCE?
In FY26, Sai Life Sciences' return on equity (ROE) was 15.1% and its return on capital employed (ROCE) was 17.8%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
What is the Sai Life Sciences market cap?
Sai Life Sciences' market capitalisation was ₹31,752 crore at the 29 October 2026 close: 21.23 crore shares at ₹1,495.70 each.
What is the Sai Life Sciences EPS?
Sai Life Sciences' basic earnings per share (EPS) were ₹16.63 in FY26, against ₹8.83 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹17.17.
When are the Sai Life Sciences next results?
Sai Life Sciences will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.
What is the Sai Life Sciences book value per share?
Sai Life Sciences' book value per share was ₹117.00 on 31 March 2026: shareholders' equity of ₹2,484 crore divided by the 21.23 crore shares in issue, up 14.6% from ₹102.12 a year earlier. The share price at the 29 October 2026 close was ₹1,495.70.
What is the Sai Life Sciences promoter holding?
Promoters held 34.50% of Sai Life Sciences on 30 September 2026, down 0.03 percentage points from 34.53% the previous quarter and down 0.44 percentage points from 34.94% a year earlier, according to the shareholding pattern filed with NSE.
What are the Sai Life Sciences latest quarterly results?
Sai Life Sciences' latest results are for Q1 FY27 (April–June 2026), filed on 6 August 2026: consolidated net profit ₹73.3 crore, up 21.2% from ₹60.5 crore in Q1 FY26; revenue from operations ₹554 crore, up 11.7% year on year.
What is the Sai Life Sciences shareholding pattern?
On 30 September 2026, Sai Life Sciences' shares were held by promoters 34.50%, foreign portfolio investors (FII/FPI) 19.91%, domestic institutions (DII) 32.32% (including mutual funds at 29.56%) and retail and other non-institutional investors 13.26%. Over the year, FII holding was down 2.59 percentage points from 22.50% and DII holding was up 2.41 percentage points from 29.91%.
How does Sai Life Sciences compare with its peers?
On FY26 consolidated figures, against Syngene International, Divi's Labs and Piramal Pharma: Sai Life Sciences' operating margin of 21.2% is the second highest of the four (Syngene International 12.5%, Divi's Labs 28.2%, Piramal Pharma 1.0%; peer average 13.9%); its return on equity of 15.1% is the second highest of the four (Syngene International 6.6%, Divi's Labs 16.2%, Piramal Pharma −4.0%; peer average 6.3%).
Sai Life Sciences vs Syngene International: how do they compare?
In FY26, Sai Life Sciences earned net profit of ₹349 crore on revenue of ₹2,192 crore, against ₹317 crore on ₹3,739 crore for Syngene International. Sai Life Sciences' operating margin was 21.2% (Syngene International 12.5%) and its return on equity 15.1% (Syngene International 6.6%). At the 29 October 2026 close, Sai Life Sciences' market capitalisation was ₹31,752 crore against ₹16,091 crore for Syngene International, and its PE ratio on FY26 profit 91.0 against 50.8.
What is the Sai Life Sciences free cash flow?
In FY26, Sai Life Sciences generated ₹509 crore of cash from operations and spent ₹593 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹83.8 crore. In FY25 it was −₹55.2 crore.
What is the Sai Life Sciences revenue and profit in FY26?
In FY26 (April 2025–March 2026), Sai Life Sciences' consolidated net profit was ₹349 crore, up 105.1% from ₹170 crore in FY25, on revenue from operations of ₹2,192 crore (up 29.4%).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
